Gibbs, Anna
Maripuu, Martin
Öhlund, Louise
Widerström, Micael
Nilsson, Niklas
Werneke, Ursula
Funding for this research was provided by:
Umea University
Article History
Received: 21 July 2023
Accepted: 20 February 2024
First Online: 7 March 2024
Declarations
:
: The study was approved by the Swedish Ethical Review Authority (Etikprövningsmyndigheten) (DNR 2020–02759, DNR 2021–05175) and conducted according to the declaration of Helsinki. The data originated from routine information collected by the Swedish Board of Health and Welfare (Socialstyrelsen), which was then made available as summary data in anonymised form. As this data was only provided in anonymised summary form, individuals could not be identified and informed consent could not be obtained. This was accepted by the Swedish Ethical Review authority so that the need for consent was waived. The Swedish Board of Health and Welfare only provided the data after ethical approval had been obtained. At this point, the Swedish Board of Health and Welfare withheld data considered potentially identifiable (data withheld due to confidentiality reasons).
: Not applicable.
: AG, LÖ, NN, MM, and MW declare no conflict of interest. UW has received funding for educational activities on behalf of Region Norrbotten, Sweden (Masterclass Psychiatry Programme 2014-2018, EAPM 2016 Luleå, Sweden): Astra Zeneca, Janssen, Eli Lilly, Novartis, Otsuka/Lundbeck, Servier, Shire and Sunovion. UW has received lecture honoraria from Lundbeck and Janssen and has served/serves on scientific committees for Janssen, receiving honoraria for these activities. UW has been a shareholder of Novo Nordisk.